当前位置: X-MOL 学术Mol. Biol. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
LncRNA-ATB in cancers: what do we know so far?
Molecular Biology Reports ( IF 2.6 ) Pub Date : 2020-04-04 , DOI: 10.1007/s11033-020-05415-5
Feng Tang 1, 2 , Yadi Xu 1, 2 , Hongliang Wang 1, 2 , Erbao Bian 1, 2 , Bing Zhao 1, 2
Affiliation  

Cancer-related deaths did not apparently decrease in the past decades despite aggressive treatments. It's reported that cancer will become the leading cause of death worldwide in the twenty-first century. Increasing evidence has revealed that lncRNAs will emerge as promising cancer biomarkers or therapeutic targets in cancer treatment. LncRNA-ATB, a long noncoding RNA activated by TGF-β, was found to be abnormally expressed in certain cancers and participate in the development and progression of tumors. In addition, aberrant lncRNA-ATB expression was also associated with clinical characteristics of tumors. The purpose of this review is to summarize functions and underlying mechanisms of lncRNA-ATB in tumors, and discuss whether lncRNA-ATB can be a biomarker and therapeutic target in cancers.

中文翻译:

LncRNA-ATB在癌症中的作用:到目前为止我们知道什么?

尽管采取了积极的治疗措施,在过去的几十年中,与癌症相关的死亡并未明显减少。据报道,癌症将成为二十一世纪全球死亡的主要原因。越来越多的证据表明,lncRNAs将成为有前途的癌症生物标志物或癌症治疗中的治疗靶标。发现LncRNA-ATB是一种由TGF-β激活的长的非编码RNA,在某些癌症中异常表达,并参与肿瘤的发生和发展。此外,lncRNA-ATB异常表达也与肿瘤的临床特征有关。这篇综述的目的是总结lncRNA-ATB在肿瘤中的功能和潜在机制,并讨论lncRNA-ATB是否可以作为癌症的生物标志物和治疗靶标。
更新日期:2020-04-06
down
wechat
bug